Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).

Original languageEnglish (US)
JournalClinics in Liver Disease
DOIs
StateAccepted/In press - 2017

Fingerprint

Cysteamine
Phase II Clinical Trials
Unsaturated Fatty Acids
Histology
Randomized Controlled Trials
Therapeutics
Non-alcoholic Fatty Liver Disease
TAK-652
6-ethylchenodeoxycholic acid
Liraglutide

Keywords

  • Cenicriviroc
  • Elafibranor
  • Liraglutide
  • NAFLD
  • NASH
  • Obeticholic acid
  • Selonsertib

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{b9cfcd183b564544b083332cb5bfbdac,
title = "Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis",
abstract = "This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).",
keywords = "Cenicriviroc, Elafibranor, Liraglutide, NAFLD, NASH, Obeticholic acid, Selonsertib",
author = "Samer Gawrieh and Naga Chalasani",
year = "2017",
doi = "10.1016/j.cld.2017.08.013",
language = "English (US)",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

AU - Gawrieh, Samer

AU - Chalasani, Naga

PY - 2017

Y1 - 2017

N2 - This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).

AB - This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).

KW - Cenicriviroc

KW - Elafibranor

KW - Liraglutide

KW - NAFLD

KW - NASH

KW - Obeticholic acid

KW - Selonsertib

UR - http://www.scopus.com/inward/record.url?scp=85030777716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030777716&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2017.08.013

DO - 10.1016/j.cld.2017.08.013

M3 - Article

C2 - 29128056

AN - SCOPUS:85030777716

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

ER -